CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA

Inclusion criteria

• Age ≥ 18 years old;
• Diagnosed with aplastic anemia (AA) through routine blood tests, bone marrow puncture, bone marrow biopsy, and exclusion tests, and determined as transfusion-dependent non-severe aplastic anemia (TD-NSAA) or severe aplastic anemia (SAA) according to the Camitta criteria; Platelet < 30×10^9/L;
• Had no HLA-matched donors or was not suitable for first-line allogeneic hematopoietic stem cell transplantation (HSCT);
• Not suitable for ATG, due to reasons such as age, complications, and the patient's own wishes;
• With baseline liver and kidney functions <2 ULN;
• ECOG score ≤ 2;
• Signed the informed consent;

Exclusion criteria

• Had other primary or secondary bone marrow failure (BMF) diseases, such as Fanconi anemia, congenital keratinization disorder, etc.;
• With evidence of clonal hematological bone marrow diseases (MDS, AML) in cytogenetics;
• PNH clone ≥ 50%;
• Received HSCT before enrollment;
• Previously used immunosuppressive treatments such as ATG, CsA, TPO receptor agonists (TPO-RAs);
• Allergic or intolerant to romiplostim N01, eltrombopag, hetrombopag, or CsA;
• Pregnant or lactating patients;
• Severe bleeding or infection that cannot be controlled by standard treatment;
• History of arterial or venous thrombosis;
• Complicated with malignant tumors;
• Participated in other clinical trials within 3 months;
• Patients considered not suitable to participate in this study by the investigator.